AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.37 USD
-1.28 (-16.73%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $6.58 +0.21 (3.30%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth D Momentum B VGM
Zacks News
Medidata (MDSO) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Medidata (MDSO) gains from solid segmental performance in Q4.
Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong
by Zacks Equity Research
Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.
STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q3.
IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
IRADIMED (IRMD) reports growth across all operating segments and geographies
Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up
by Zacks Equity Research
Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.
Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.
LabCorp's (LH) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
LabCorp's (LH) Q4 earnings gain on strength in the Covance Drug Development business.
Cardinal Health (CAH) Beats on Q2 Earnings, Ups FY19 View
by Zacks Equity Research
Cardinal Health's (CAH) Q2 results benefit from strong sales in the Pharmaceutical segment. An upbeat guidance is indicative of brighter prospects.
Haemonetics (HAE) Earnings Top, Revenues Lag Estimates in Q3
by Zacks Equity Research
Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
Boston Scientific (BSX) Beats on Q4 Earnings, Margins Dip
by Zacks Equity Research
Boston Scientific (BSX) is leaving no stone unturned to strengthen its core businesses and invest in global markets, which accounted for the uptick in sales across all geographies.
Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) Q2 performance by Hereditary Cancer testing is encouraging while GeneSight test revenues disappoint.
Cerner (CERN) Q4 Earnings Meet Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) gains from solid segmental revenues in fourth-quarter 2018. However, the company's 2019 guidance disappoints.
Luminex (LMNX) Q4 Earnings Miss, 2019 Guidance Lacks Luster
by Zacks Equity Research
Luminex (LMNX) gains from core Consumable unit's strong fourth-quarter show.
QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark
by Zacks Equity Research
QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.
Becton, Dickinson (BDX) Q1 Earnings In Line With Estimates
by Zacks Equity Research
Strong segmental performance favors Becton, Dickinson's (BDX) fiscal Q1 results.
Omnicell Solid on Geographic Expansion Amid Stiff Competition
by Zacks Equity Research
Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.
AngioDynamics (ANGO) Up 8.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX (IDXX) Q4 Earnings Top Estimates, Raises '19 EPS View
by Zacks Equity Research
IDEXX's (IDXX) Q4 top line was driven by strong global gains in CAG Diagnostics recurring revenues along with expansion in global premium instrument installed base.
PerkinElmer (PKI) Q4 Earnings Beat, Diagnostics Grows Y/Y
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter 2018 results gain from solid segmental contributions.
McKesson (MCK) Beats on Q3 Earnings, Gains From Solid View
by Zacks Equity Research
McKesson (MCK) gains from the U.S. Pharmaceutical and Specialty Solutions segment in third-quarter fiscal 2019.
Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Meet
by Zacks Equity Research
Cardiovascular Systems (CSII) benefits from year-over-year growth in both Coronary and peripheral device segments.
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Revenues Top
by Zacks Equity Research
Zimmer Biomet (ZBH) sees strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business in Q4.
Edwards Lifesciences (EW) Q4 Earnings In Line, Revenues Top
by Zacks Equity Research
Edwards Lifesciences (EW) Q4 results benefit from growth in all the businesses.
ABIOMED (ABMD) Q3 Earnings Beat, Impella Maintains Momentum
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella sees a solid Q3; fiscal 2019 outlook raised.
Hologic's (HOLX) Q1 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Hologic (HOLX) gains from solid double-digit constant currency growth in core businesses like U.S. Breast Health, International and Global Molecular Diagnostics.